The efficacy and safety of ramucirumab plus docetaxel in older patients with advanced non‐small cell lung cancer

BACKGROUND: Ramucirumab plus docetaxel (RAM+DOC) is expected to prolong survival in patients with advanced non‐small cell lung cancer (NSCLC); however, the efficacy and safety for older patients remains unknown. The objective of this study was to evaluate the efficacy and safety of RAM+DOC in patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakaguchi, Tadashi, Furuya, Naoki, Ito, Kentaro, Hida, Naoya, Morikawa, Kei, Komase, Yuko, Inoue, Takeo, Hataji, Osamu, Mineshita, Masamichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7262941/
https://www.ncbi.nlm.nih.gov/pubmed/32291896
http://dx.doi.org/10.1111/1759-7714.13429

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7262941/
https://www.ncbi.nlm.nih.gov/pubmed/32291896
http://dx.doi.org/10.1111/1759-7714.13429

Ejemplares similares